NASDAQ:ENZY - Enzymotec Stock Price, Price Target & More

$11.85 -0.02 (-0.17 %)
(As of 04/26/2018 07:46 AM ET)
Previous Close$11.88
Today's Range$11.85 - $11.90
52-Week Range$6.30 - $12.35
Volume98,500 shs
Average Volume120,557 shs
Market Capitalization$277.62 million
P/E RatioN/A
Dividend YieldN/A
Beta1.22

About Enzymotec (NASDAQ:ENZY)

Enzymotec logoEnzymotec Ltd. is a nutritional ingredients and medical foods company. The Company's technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company's segments offer a range of products that leverage its lipid-related offerings. Its product suite addresses the entire human life-cycle, from infancy to old age, and comprises ingredients in products ranging from infant formula to nutritional supplements, as well as branded medical foods, sold only under a doctor's supervision. It markets its product portfolio to established global consumer companies and physicians and target large and growing consumer health and wellness markets. The Company's clinically-validated products include bio-functional lipid-based compounds designed to address dietary needs, medical disorders and common diseases.

Receive ENZY News and Ratings via Email

Sign-up to receive the latest news and ratings for ENZY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:ENZY
CUSIPN/A
Phone+972-7-47177177

Debt

Debt-to-Equity RatioN/A
Current Ratio5.24%
Quick Ratio3.62%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E Ratio237.00
P/E Growth3.19

Sales & Book Value

Annual Sales$47.70 million
Price / Sales5.82
Cash Flow$0.0565 per share
Price / Cash209.80
Book Value$6.00 per share
Price / Book1.98

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-2,920,000.00
Net Margins2.32%
Return on Equity1.24%
Return on Assets0.84%

Miscellaneous

Employees205
Outstanding Shares23,430,000

How to Become a New Pot Stock Millionaire

Enzymotec (NASDAQ:ENZY) Frequently Asked Questions

What is Enzymotec's stock symbol?

Enzymotec trades on the NASDAQ under the ticker symbol "ENZY."

How were Enzymotec's earnings last quarter?

Enzymotec Ltd (NASDAQ:ENZY) released its quarterly earnings data on Wednesday, May, 17th. The biotechnology company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.06 by $0.03. The biotechnology company earned $12 million during the quarter, compared to the consensus estimate of $14.23 million. Enzymotec had a return on equity of 1.24% and a net margin of 2.32%. The business's revenue was down 14.3% on a year-over-year basis. During the same period last year, the company earned $0.09 EPS. View Enzymotec's Earnings History.

What price target have analysts set for ENZY?

2 brokers have issued 1-year price targets for Enzymotec's shares. Their predictions range from $11.50 to $12.00. On average, they anticipate Enzymotec's share price to reach $11.75 in the next year. View Analyst Ratings for Enzymotec.

Who are Enzymotec's key executives?

Enzymotec's management team includes the folowing people:
  • Steve Dubin, Independent Chairman of the Board (Age 60)
  • Erez Israeli, President, Chief Executive Officer (Age 48)
  • Yoav Doppelt, Independent Vice Chairman of the Board (Age 48)
  • Dror Israel, Chief Financial Officer, Vice President (Age 46)
  • Yoav Kahane, Chairman of Advanced Lipids AB (Age 42)
  • Yoni Twito, Chief Operating Officer (Age 47)
  • Naama Zamir, Vice President - Human Resources and Information Systems (Age 43)
  • Gai Ben-Dror, Vice President - Process Development (Age 45)
  • Tzafra Cohen, Vice President - Research & Development (Age 47)
  • Tamar D. Howson, Director (Age 68)

Has Enzymotec been receiving favorable news coverage?

News articles about ENZY stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Enzymotec earned a media sentiment score of 0.11 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 47.08 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

How do I buy shares of Enzymotec?

Shares of ENZY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Enzymotec's stock price today?

One share of ENZY stock can currently be purchased for approximately $11.85.

How big of a company is Enzymotec?

Enzymotec has a market capitalization of $277.62 million and generates $47.70 million in revenue each year. Enzymotec employs 205 workers across the globe.

How can I contact Enzymotec?

Enzymotec's mailing address is Sagi 2000 Industrial Park Migdal HaEmeq P.O. Box6, MIGDAL HAEMEQ, 23106, Israel. The biotechnology company can be reached via phone at +972-7-47177177 or via email at [email protected]


MarketBeat Community Rating for Enzymotec (ENZY)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  108 (Vote Outperform)
Underperform Votes:  161 (Vote Underperform)
Total Votes:  269
MarketBeat's community ratings are surveys of what our community members think about Enzymotec and other stocks. Vote "Outperform" if you believe ENZY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENZY will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Enzymotec (NASDAQ:ENZY) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Enzymotec in the last 12 months. Their average twelve-month price target is $11.75, suggesting that the stock has a possible downside of 0.84%. The high price target for ENZY is $12.00 and the low price target for ENZY is $11.50. There are currently 2 hold ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.002.002.00
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $11.75$11.75$11.75$11.50
Price Target Upside: 0.84% downside4.44% upside4.44% upside3.14% upside

Enzymotec (NASDAQ:ENZY) Consensus Price Target History

Price Target History for Enzymotec (NASDAQ:ENZY)

Enzymotec (NASDAQ:ENZY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/30/2017Wells FargoBoost Price TargetMarket Perform$9.50 -> $12.00N/AView Rating Details
10/19/2017Jefferies GroupReiterated RatingHold$11.50N/AView Rating Details
(Data available from 4/26/2016 forward)

Earnings

Enzymotec (NASDAQ:ENZY) Earnings History and Estimates Chart

Earnings by Quarter for Enzymotec (NASDAQ:ENZY)

Enzymotec (NASDAQ:ENZY) Earnings Estimates

Current Year EPS Consensus Estimate: $0.05 EPS
Next Year EPS Consensus Estimate: $0.31 EPS

Enzymotec (NASDAQ ENZY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/15/2017Q3 2017$0.07$0.04$14.36 million$13.67 millionViewN/AView Earnings Details
8/16/20176/30/2017$0.05($0.10)$12.78 million$13.00 millionViewN/AView Earnings Details
5/17/20173/31/2017$0.06$0.03$14.23 million$12.00 millionViewN/AView Earnings Details
2/22/2017Q416$0.03($0.10)$11.47 million$10.60 millionViewN/AView Earnings Details
11/16/2016Q316$0.07$0.03$13.29 million$11.40 millionViewN/AView Earnings Details
8/9/2016Q216$0.08$0.04$14.90 million$15.00 millionViewN/AView Earnings Details
5/19/2016Q116$0.05$0.09$13.85 million$14.00 millionViewListenView Earnings Details
2/17/2016Q415$0.10$0.07$14.01 million$13.30 millionViewListenView Earnings Details
11/11/2015Q315$0.07$0.08$14.21 million$12.40 millionViewListenView Earnings Details
8/12/2015Q215$0.06$0.11$12.39 million$13.40 millionViewListenView Earnings Details
5/7/2015Q115$0.06$0.09$12.10 million$12.25 millionViewN/AView Earnings Details
2/18/2015Q414$0.08$0.06$11.11 million$10.80 millionViewN/AView Earnings Details
11/13/2014Q314$0.04$0.05$10.22 million$9.50 millionViewN/AView Earnings Details
8/5/2014Q214$0.10$0.02$14.88 million$11.50 millionViewN/AView Earnings Details
5/14/2014Q114$0.17$0.24$19.40 million$23.70 millionViewN/AView Earnings Details
2/13/2014Q413$0.11$0.15$11.64 million$18.51 millionViewN/AView Earnings Details
11/11/2013Q313$0.11$0.13$13.10 million$22.50 millionViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Enzymotec (NASDAQ:ENZY) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Enzymotec (NASDAQ ENZY) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 15.73%
Insider Trading History for Enzymotec (NASDAQ:ENZY)
Institutional Ownership by Quarter for Enzymotec (NASDAQ:ENZY)

Enzymotec (NASDAQ ENZY) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Enzymotec (NASDAQ ENZY) News Headlines

Source:
DateHeadline
Reviewing Calgon Carbon (CCC) & Enzymotec (ENZY)Reviewing Calgon Carbon (CCC) & Enzymotec (ENZY)
www.americanbankingnews.com - March 30 at 7:14 PM
Reviewing Enzymotec (ENZY) & Calgon Carbon (CCC)Reviewing Enzymotec (ENZY) & Calgon Carbon (CCC)
www.americanbankingnews.com - March 27 at 9:25 AM
Analyzing Taminco (TAM) & Enzymotec (ENZY)Analyzing Taminco (TAM) & Enzymotec (ENZY)
www.americanbankingnews.com - March 17 at 7:08 PM
Calgon Carbon (CCC) versus Enzymotec (ENZY) Head-To-Head ContrastCalgon Carbon (CCC) versus Enzymotec (ENZY) Head-To-Head Contrast
www.americanbankingnews.com - March 9 at 5:42 PM
Water Island Capital LLC Takes $4.74 Million Position in Enzymotec Ltd (ENZY)Water Island Capital LLC Takes $4.74 Million Position in Enzymotec Ltd (ENZY)
www.americanbankingnews.com - March 2 at 9:50 PM
Comparing Enzymotec (ENZY) & Calgon Carbon (CCC)Comparing Enzymotec (ENZY) & Calgon Carbon (CCC)
www.americanbankingnews.com - March 1 at 7:16 PM
Enzymotec (ENZY) to Release Quarterly Earnings on TuesdayEnzymotec (ENZY) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - February 13 at 2:56 AM
Trecora Resources (TREC) & Enzymotec (ENZY) Critical ContrastTrecora Resources (TREC) & Enzymotec (ENZY) Critical Contrast
www.americanbankingnews.com - January 28 at 7:12 PM
BidaskClub Downgrades Enzymotec (ENZY) to SellBidaskClub Downgrades Enzymotec (ENZY) to Sell
www.americanbankingnews.com - January 6 at 7:28 PM
Enzymotec Ltd (ENZY) Receives Consensus Recommendation of "Hold" from BrokeragesEnzymotec Ltd (ENZY) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - January 6 at 4:02 PM
Enzymotec Ltd. :ENZY-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018Enzymotec Ltd. :ENZY-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018
finance.yahoo.com - January 1 at 9:22 AM
Zacks: Brokerages Set $9.50 Target Price for Enzymotec Ltd (ENZY)Zacks: Brokerages Set $9.50 Target Price for Enzymotec Ltd (ENZY)
www.americanbankingnews.com - December 29 at 5:52 AM
 Enzymotec Ltd (ENZY) Given Consensus Rating of "Hold" by Brokerages Enzymotec Ltd (ENZY) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - December 21 at 11:52 AM
Enzymotec (ENZY) Shareholders Approve Proposed Acquisition by FrutaromEnzymotec (ENZY) Shareholders Approve Proposed Acquisition by Frutarom
www.streetinsider.com - December 12 at 5:52 PM
BRIEF-Enzymotec Shareholders Approve Proposed Acquisition By FrutaromBRIEF-Enzymotec Shareholders Approve Proposed Acquisition By Frutarom
www.reuters.com - December 12 at 5:52 PM
Merger Deal between Enzymotec and Frutarom Approved by 99.9% Majority of Enzymotec ShareholdersMerger Deal between Enzymotec and Frutarom Approved by 99.9% Majority of Enzymotec Shareholders
finance.yahoo.com - December 12 at 9:52 AM
Analysts Expect Enzymotec Ltd. (ENZY) to Post $0.08 EPSAnalysts Expect Enzymotec Ltd. (ENZY) to Post $0.08 EPS
www.americanbankingnews.com - December 6 at 7:46 PM
Celanese (CE) versus Enzymotec (ENZY) Critical ReviewCelanese (CE) versus Enzymotec (ENZY) Critical Review
www.americanbankingnews.com - November 27 at 7:48 AM
Frutarom Industries (FRUTF) CEO Ori Yehudai on Q3 2017 Results - Earnings Call TranscriptFrutarom Industries' (FRUTF) CEO Ori Yehudai on Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - November 22 at 4:38 AM
Zacks: Enzymotec Ltd. (ENZY) Receives Consensus Rating of "Hold" from BrokeragesZacks: Enzymotec Ltd. (ENZY) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - November 20 at 12:16 PM
Contrasting Enzymotec (ENZY) and PQ Group Holdings (PQG)Contrasting Enzymotec (ENZY) and PQ Group Holdings (PQG)
www.americanbankingnews.com - November 18 at 9:08 PM
Enzymotec Ltd. Reports Third Quarter 2017 Unaudited Financial ResultsEnzymotec Ltd. Reports Third Quarter 2017 Unaudited Financial Results
finance.yahoo.com - November 16 at 1:55 PM
Enzymotec posts 3Q profitEnzymotec posts 3Q profit
finance.yahoo.com - November 16 at 1:55 PM
Enzymotec Ltd. (ENZY) Scheduled to Post Earnings on TuesdayEnzymotec Ltd. (ENZY) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - November 7 at 3:04 AM
Enzymotec Ltd. Calls 2017 Annual And Extraordinary General Meeting Of Shareholders For Approval Of Merger And Other MattersEnzymotec Ltd. Calls 2017 Annual And Extraordinary General Meeting Of Shareholders For Approval Of Merger And Other Matters
www.thestreet.com - November 2 at 7:32 PM
Enzymotec Ltd. Calls 2017 Annual and Extraordinary General Meeting of Shareholders for Approval of Merger and Other MattersEnzymotec Ltd. Calls 2017 Annual and Extraordinary General Meeting of Shareholders for Approval of Merger and Other Matters
finance.yahoo.com - November 2 at 7:32 PM
Wells Fargo & Company Raises Enzymotec Ltd. (ENZY) Price Target to $12.00Wells Fargo & Company Raises Enzymotec Ltd. (ENZY) Price Target to $12.00
www.americanbankingnews.com - October 30 at 9:52 PM
Enzymotec Enters Definitive Agreement to be Acquired by FrutaromEnzymotec Enters Definitive Agreement to be Acquired by Frutarom
finance.yahoo.com - October 29 at 4:40 AM
Frutarom Will Acquire Full Ownership of the Specialty Nutrition Company Enzymotec at a Net Investment of Approx. USD 210MFrutarom Will Acquire Full Ownership of the Specialty Nutrition Company Enzymotec at a Net Investment of Approx. USD 210M
finance.yahoo.com - October 29 at 4:40 AM
Israeli flavour firm Frutarom to buy remaining 81 pct of EnzymotecIsraeli flavour firm Frutarom to buy remaining 81 pct of Enzymotec
finance.yahoo.com - October 29 at 4:40 AM
Sale of NKY health care firm leads to departure of executiveSale of NKY health care firm leads to departure of executive
www.bizjournals.com - October 26 at 1:13 PM
Enzymotec Ltd (ENZY) Rating Reiterated by Jefferies Group LLCEnzymotec Ltd (ENZY) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - October 22 at 9:06 PM
Enzymotec Ltd. (ENZY) Stock Rating Upgraded by Zacks Investment ResearchEnzymotec Ltd. (ENZY) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - October 17 at 11:38 PM
Enzymotec (ENZY) & Its Peers Financial ComparisonEnzymotec (ENZY) & Its Peers Financial Comparison
www.americanbankingnews.com - October 8 at 8:08 PM
Enzymotec Ltd. :ENZY-US: Earnings Analysis: Q2, 2017 By the Numbers : October 5, 2017Enzymotec Ltd. :ENZY-US: Earnings Analysis: Q2, 2017 By the Numbers : October 5, 2017
finance.yahoo.com - October 5 at 5:28 PM
Enzymotec (ENZY) versus Praxair (PX) Head-To-Head ComparisonEnzymotec (ENZY) versus Praxair (PX) Head-To-Head Comparison
www.americanbankingnews.com - October 5 at 6:26 AM
Form SC14D9C Enzymotec Ltd. Filed by: Enzymotec Ltd. - StreetInsider.comForm SC14D9C Enzymotec Ltd. Filed by: Enzymotec Ltd. - StreetInsider.com
www.streetinsider.com - September 27 at 6:33 PM
BRIEF-Enzymotec ltd says on Sept. 24, Steve Dubin, chairman of Enzymotec sent letter to Ori Yehudai, President and ... - ReutersBRIEF-Enzymotec ltd says on Sept. 24, Steve Dubin, chairman of Enzymotec sent letter to Ori Yehudai, President and ... - Reuters
www.reuters.com - September 27 at 6:33 PM
Saxena White P.A. Announces a Proposed Settlement Involving All Persons who Purchased or Otherwise Acquired Enzymotec Common StockSaxena White P.A. Announces a Proposed Settlement Involving All Persons who Purchased or Otherwise Acquired Enzymotec Common Stock
www.businesswire.com - September 25 at 11:25 AM
Enzymotec (ENZY) vs. Its Competitors Critical ContrastEnzymotec (ENZY) vs. Its Competitors Critical Contrast
www.americanbankingnews.com - September 16 at 12:10 AM
Critical Comparison: Enzymotec (ENZY) vs. Innophos Holdings (IPHS)Critical Comparison: Enzymotec (ENZY) vs. Innophos Holdings (IPHS)
www.americanbankingnews.com - September 11 at 8:54 AM
Head to Head Survey: NewMarket Corporation (NEU) and Enzymotec (ENZY)Head to Head Survey: NewMarket Corporation (NEU) and Enzymotec (ENZY)
www.americanbankingnews.com - September 9 at 10:24 AM
Head-To-Head Contrast: Enzymotec (ENZY) & Albemarle Corporation (ALB)Head-To-Head Contrast: Enzymotec (ENZY) & Albemarle Corporation (ALB)
www.americanbankingnews.com - September 1 at 9:10 AM
Enzymotec (ENZY) Reports Acquisition of Five Nurtritional Supplements from Union Springs Healthcare LLCEnzymotec (ENZY) Reports Acquisition of Five Nurtritional Supplements from Union Springs Healthcare LLC
www.streetinsider.com - August 30 at 7:34 PM
Enzymotec Ltd. Expands VAYA Product Portfolio with Five Nutritional Supplements Acquired from Union Springs HealthcareEnzymotec Ltd. Expands VAYA Product Portfolio with Five Nutritional Supplements Acquired from Union Springs Healthcare
finance.yahoo.com - August 30 at 7:34 PM
Enzymotec (ENZY) & Eastman Chemical (EMN) Head-To-Head AnalysisEnzymotec (ENZY) & Eastman Chemical (EMN) Head-To-Head Analysis
www.americanbankingnews.com - August 30 at 6:28 AM
BRIEF-Enzymotec Ltd responds to unsolicited proposal from Frutarom LtdBRIEF-Enzymotec Ltd responds to unsolicited proposal from Frutarom Ltd
www.reuters.com - August 28 at 11:07 PM
Enzymotec Advises Shareholders To Defer Decision On Frutaroms ProposalEnzymotec Advises Shareholders To Defer Decision On Frutarom's Proposal
www.nasdaq.com - August 28 at 11:07 PM
Enzymotec (ENZY) Comments on Unsolicited Proposal from FrutaromEnzymotec (ENZY) Comments on Unsolicited Proposal from Frutarom
www.streetinsider.com - August 28 at 11:07 PM
Corporate News Blog - Genetic Technologies Announces Comprehensive Review of Strategic AlternativesCorporate News Blog - Genetic Technologies Announces Comprehensive Review of Strategic Alternatives
finance.yahoo.com - August 28 at 6:05 PM

SEC Filings

Enzymotec (NASDAQ:ENZY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Enzymotec (NASDAQ:ENZY) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Enzymotec (NASDAQ ENZY) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.